French Medical Campaign Targets Cardiac Amyloidosis
Cardiac amyloidosis affects approximately 10,000 people in France, where health authorities have launched a national awareness campaign to shorten a diagnostic delay that typically spans two to four years, Les Echos reported. Also known as the “chameleon disease,” transthyretin cardiac amyloidosis involves the progressive accumulation of abnormal protein aggregates in organs, tendons, ligaments, joints, and the inner ear. Early detection increases survival chances by 40%, yet patients often experience years of unrelated symptoms before the condition damages the heart muscle.
Early Signs That Precede Heart Damage
Before amyloid deposits stiffen the heart walls and restrict blood flow between beats, the condition frequently manifests through rheumatological, orthopedic, or ear, nose, and throat disorders. According to reporting from Charente Libre, these early warning signs can precede cardiac involvement by five to ten years. Clinicians are being urged to recognize and connect symptoms that patients often report years prior to a formal diagnosis.
The primary physical indicators include:
* Bilateral or recurrent carpal tunnel syndrome, where the median nerve remains compressed in both wrists.
* Spontaneous rupture of the long biceps tendon or the rotator cuff.
* Narrowing of the lumbar or cervical spinal canal, leading to sciatic or crural pain.
* Dupuytren’s disease or trigger finger.
* Hip or knee osteoarthritis requiring joint replacement surgery.
* Progressive hearing loss.
* Shortness of breath, fatigue, rapid weight gain, or edema.
How Amyloid Deposits Rigidify the Heart
When amyloid fibrils infiltrate cardiac tissue, they surround heart cells and isolate them, disrupting normal electrical and mechanical function. Progress reported that the muscle walls thicken and stiffen, preventing the heart from filling adequately with blood during diastole, resulting in a condition known as restrictive cardiomyopathy. The abnormal deposits can also damage the heart’s electrical system, heart valves, and coronary arteries through microvascular involvement.
National Screening and Diagnostic Goals
To address the typical two-to-four-year delay in identifying the disease, medical societies and patient associations launched a national campaign dubbed “Maladie caméléon” on September 11. As part of this initiative, a national screening program is scheduled to begin on October 26 across nearly 50 hospital centers throughout France.
“This campaign invites all health professionals to change their perspective on these signs, to link them together, and to think earlier about cardiac amyloidosis,” noted Pr Thomas Bardin, a rheumatologist and national coordinator of the campaign, as cited by Charente Libre.
Frequently Asked Questions About Cardiac Amyloidosis
What is the most common form of cardiac amyloidosis?
Transthyretin cardiac amyloidosis is the most frequently diagnosed form of the condition, driven by the accumulation of abnormal protein fibers that stiffen organ tissues.
How much does early detection improve patient survival rates?
Chances of survival increase by 40% when the condition is detected and treated in its early stages before severe heart muscle stiffening occurs.
Where and when will the upcoming screening take place in France?
A national screening effort begins on October 26 across approximately 50 hospital centers nationwide to help reduce diagnostic delays for the estimated 10,000 affected individuals.
Related reading